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ABBREVIATIONS 
CCS-Bayley-III Cognitive composite score – Bayley Scales of Infant Development (3rd 
edition)  
DHA   Docosahexaenoic acid 
LCS-Bayley-III Language composite score – Bayley Scales of Infant Development (3rd 
edition)  
UMP   Uridine-5-monophosphate 
VABS-II  Vineland Adaptive Behavior Scales (2nd edition) 
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[Abstract] 
AIM To investigate whether docosahexaenoic acid, choline, and uridine-5-monophosphate 
supplementation improves neurodevelopmental outcome in infants with suspected cerebral 
palsy (CP) versus a comparison group of children. 
METHOD Infants aged 1 to 18 months with suspected CP were recruited from UK child 
development centres. Participants received daily treatment or control supplementation for 2 
years (double-blind randomized control design). Stratification was by age, sex, predominant 
pattern of motor involvement (four limbs or other), and visual impairment (yes or no). The 
primary outcome was the cognitive composite score of the Bayley Scales of Infant 
Development (3rd edition) (CCS-Bayley-III). Secondary outcomes included language 
composite and motor composite scores of the Bayley-III. 
RESULTS Forty infants were recruited; 35 began supplementation, 29 completed 1 to 2 
years’ supplementation. The treatment group CCS-Bayley-III was non-significantly higher 
than the comparison group (mean 77.7 [SD 19.2] and 72.2 [SD 19.8] respectively, mean 
modelled difference 4.4 [−2.8, 11.6]). The treatment group language scores, but not motor 
scores, were non-significantly higher than for the comparison group. 
INTERPRETATION Most families found supplementation feasible. No statistically 
significant differences in neurodevelopmental outcome between the treatment and 
comparison groups were identified. Further investigation of neurodevelopmental outcome 
following supplementation with docosahexaenoic acid, choline, and uridine-5-
monophosphate of infants with suspected CP is warranted. 
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What this paper adds 
 The first trial of phosphatidylcholine precursor supplementation in infants with suspected 
cerebral palsy (CP). 
 Families of infants with suspected CP found 2-year nutritional supplementation feasible. 
 No statistically significant neurodevelopmental advantage for the treatment group versus 
the comparison group. 
 However, treatment group cognitive and language advantage were of clinically 
meaningful magnitude. 
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The developing brain may have some capacity to alter its structure and function in response 
to injury through processes of plasticity. There may be ‘critical periods’ or temporal windows 
in brain development during which there is increased potential for plasticity associated with 
maximal neural sensitivity to specific stimuli. These are periods of rapid neural maturation 
and extensive neural connectivity. Adequate macro- and micronutrient intake are essential for 
healthy brain development and can be manipulated in an attempt to support optimal 
neurodevelopmental outcome in at-risk groups.1,2 The structure and function of the central 
nervous system relies on a specific profile of phospholipids and their fatty acids. 
Phosphatidylcholine is the most abundant brain phospholipid, and comprises choline (an 
amine), uridine-5-monophosphate (UMP), a pyrimidine, and the long-chain polyunsaturated 
fatty acid docosahexaenoic acid (DHA).3 This process is rate-limited by the nutritional 
availability of DHA, UMP, and choline. DHA is also necessary for neurogenesis, neurite 
outgrowth, synaptic plasticity, axonal elimination, and gene expression.4–8 Choline is a source 
of methyl groups (necessary for methylation of DNA and ribonucleic acid), a component of 
phosphatidylcholine and sphingomyelin, and is necessary for the production of the 
neurotransmitter acetylcholine.9 UMP is important for synapse membrane production.10 As 
adequate macro- and micronutrient intake is needed to support brain development, nutritional 
inadequacy may limit the brain’s capacity for remodelling and repair after injury.11 Rodent 
supplementation with a combination of DHA, choline, and UMP increases brain phosphatide 
levels, synaptic components, functional brain connectivity, and cognitive performance.12 
Brain injury occurring in the first 2 years of life, during maximal brain growth and 
development, may result in cerebral palsy (CP); ‘a group of permanent disorders of 
movement and posture, causing activity limitation, which are attributed to non-progressive 
disturbances that occurred in the developing fetal or infant brain. The motor disorders of CP 
are often accompanied by disturbances of sensation, perception, cognition, communication, 
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and behaviour, by epilepsy, and by secondary musculoskeletal problems’.13 CP remains a 
major cause of childhood disability worldwide, with a prevalence of 2 per 1000 live births.14 
Feeding difficulties such as oromotor impairment, dysphagia, and foregut dysmotility are 
common in children with CP11 and may result in prolonged feeding times, reduced macro- 
and micronutrient intake, and growth failure without adequate nutritional support. 
Gastrostomy placement may be necessary to support optimal nutrition and growth for 
children with CP.15,16 Many feeding and nutritional interventions for children with CP are 
introduced once growth failure is already established, but they lack high-quality evidence of 
benefit.17,18 
Novel early nutritional interventions aimed at reducing the level of disability 
experienced by children with CP are needed.19 This study investigated whether nutritional 
intervention with DHA, choline, and uridine supplementation at maximal permissible levels 
improved neurodevelopmental outcomes in infants with suspected CP. 
 
METHOD 
We conducted a double-blind randomized placebo-controlled trial of DHA, choline, and 
uridine in infants with suspected CP. The trial protocol provides the full methodology 
(https://bmcpediatr.biomedcentral.com/articles/10.1186/s12887-015-0339-2).20 
 
Participants 
Consultant paediatricians from five collaborating multidisciplinary child development teams 
in the UK (Oxford, Reading, Slough, Milton Keynes, and High Wycombe/Aylesbury) 
identified eligible infants. Inclusion criteria were children aged 1 to 18 months with suspected 
CP. Exclusion criteria were children with (1) progressive neurological conditions, or 
investigational evidence of non-CP neurological conditions which may initially mimic CP, 
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(2) hearing impairments, unable to complete trial assessments, (3) gastrointestinal disease 
impairing absorption, (4) parents considered unable to follow the study protocol by clinicians, 
or (5) participants of a contemporaneous parallel randomized controlled trial assessing the 
neurodevelopmental outcomes of neonates with risk factors for neurodevelopmental 
impairments following dietary supplementation.20 
Paediatricians at participating child development centres identified families interested 
in receiving additional trial information to the research team. The research nurse sent the trial 
parent information sheet to interested families and arranged follow-up to answer any 
parental/carer questions after 5 to 7 days. Informed written consent was obtained from 
participating families during a home visit then followed by trial baseline assessments. Study 
ethical approval was granted by the Oxfordshire Research Ethics Committee B. 
Participants were randomized by the University of Oxford’s Centre for Statistics in 
Medicine, by minimization, stratifying by sex, age at randomization (1–5mo, 6–12mo, and 
13–18mo), and pattern of motor involvement (four limbs or other) and visual impairment 
(yes/no). The trial principal investigators and team conducting neurodevelopmental 
assessments were blind to group allocation. The trial dietitian and research administrator 
were not blind to group allocation, but did not discuss children’s treatment with other team 
members or parents. All information about group allocation and dietary information was held 
separately to the case report form, and accessed only by the research administrator or 
dietitian. The trial dietitian delivered product to the families. 
Participants received daily treatment or control supplementation for 2 years. The 
study supplements were produced and quality control checked by Nutricia Advanced Medical 
Nutrition, Utrecht, the Netherlands. The active supplement contained omega-3 fatty acids 
DHA (1% of total daily estimated fatty-acid intake), eicosapentaenoic acid, the omega-6 fatty 
acid arachidonic acid, choline, UMP, cytosine monophosphate, vitamin B12, zinc, and iodine, 
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nutrients that are also important to brain development21 (Table I). Treatment and control 
supplement were produced on a background of infant formula and therefore contained a small 
amount of choline, vitamins, minerals, and trace elements. 
The supplement products were processed to be similar in odour and/or taste and 
supplied in identical foil packages marked X and Y. Infants received 2g/kg/day (maximum 
24g/d), supplied as a combination of 2g, 3g, and 12g sachets, for 2 years, or while compliant 
with the study protocol. The supplement was mixed with usual formula or expressed breast 
milk and with wet foods on weaning, or delivered through a feeding tube. The trial dietician 
telephoned each family every 2 weeks initially, then as required, and made 3-monthly 
assessment visits to optimize dietary macro- and micronutritional intake, supplement 
tolerance, adherence, and growth, and to provide supplement. 
Study assessments and their timing are described in the trial protocol.20 The Bayley 
Scales of Infant Development (3rd edition) (Bayley-III) were administered to children at 
baseline, 12 months, and 24 months in the child’s home by one of two trained assessors (MJA 
or CM-J). The Vineland Adaptive Behavior Scales (2nd edition) (VABS-II) was administered 
to the parent (MJA or CM-J) following Bayley assessment. Neurophysiological and 
functional behavioural visual measures were performed at baseline, 12 months, and 24 
months. Occipito-frontal circumference was measured using a Lasso-o tape measure at 
baseline and every 3 months. A mean from three measurements of the occipito-frontal 
circumference was calculated. One confidently obtained measurement was accepted in 
infants not compliant with measurement. Height, weight, and triceps skinfold thickness were 
also measured every 3 months.20 
Home dietary assessment occurred every 3 months. Dietary history using food recall 
over the previous week was recorded and used to advise families on optimal macro- and 
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micronutrient intake. Dietary data were analysed using Dietplan 6 (Forestfield Software Ltd, 
UK). 
Whole-blood fatty-acid samples were collected from participants by heel prick onto a 
Guthrie card at baseline and 24 months, and analysed using the method of Marangoni et al.22 
The primary outcome was the cognitive composite score of the Bayley Scales of 
Infant Development (3rd edition) (CCS-Bayley-III)  at 24 months of supplementation. The 
Bayley-III is a standardized measure of neurodevelopment suitable for children aged 1 to 42 
months with cognitive, language, and motor domains.23 The Bayley-III composite score has a 
range of 40 to 160 and is a normalized transformation of a distribution of scores derived from 
normative tables of standardized scaled scores, composite scores, and percentile ranks 
provided in the Bayley-III manual. 
Reported secondary outcomes included the CCS-Bayley-III scores at 12 months, and 
language composite score of the Bayley Scales of Infant Development (3rd edition) (LCS-
Bayley-III) and motor composite score of the Bayley-III at 12 and 24 months. Parent-reported 
adaptive behaviour scores were measured by the VABS-II, a standardized parent 
questionnaire assessing adaptive behaviour from birth to 90 years.24 The measure provides a 
standard adaptive composite score standardized and normed for age (mean 100, SD 15), 
derived from standardized domain scores: communication, socialization, and daily living 
skills. 
 
Statistical analysis 
Statistical analysis was conducted according to the trial statistical analysis plan using STATA 
14.1 (StataCorp, College Station, TX, USA, 2015). Sample size was calculated for 80% 
power to detect a 12.5-point difference in CCS-Bayley-III, at the 5% level for a two-tailed 
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test. In total, a sample size of 48 participants were required, assuming an SD of 15. Assuming 
a 20% loss to follow-up, the recruitment target was increased to a total of 60 children. 
Bayley-III scores at 12 and 24 months of supplementation were analysed using 
mixed-effects linear regression to account for repeated measures at 12 and 24 months. The 
model covariates were baseline Bayley-III score, time point (12mo/24mo), treatment group, 
an interaction between time point and treatment group, and the minimization factors of 
predominant pattern of motor development (four limbs or other), age at recruitment (1–5mo, 
6–12mo, and 13–18mo), sex, and visual impairment (yes or no). 
For primary outcome analysis, mean differences in CCS-Bayley-III between 
intervention groups at 24 months of supplementation are presented along with 95% 
confidence intervals (CI) and associated two-sided p-values, and the p-value for overall effect 
of treatment. No adjustment of p-values to account for multiple endpoints was made. 
Analyses of secondary Bayley-III and VABS-II outcomes follow the procedure described for 
the primary outcome analysis. 
Anthropometric measurements were converted to z-scores before analysis. The z-
scores were calculated using the World Health Organization Child Growth Standards STATA 
igrowup package (WHO Multicentre Growth Reference Study Group, 2007; 
http://www.who.int/childgrowth/software/readme_sas.pdf). 
Mixed-effects regression models were fitted to the data, and the fitted difference in 
means between treatment and comparison groups at 12 and 24 months presented alongside 
95% CI and the associated two-sided p-values for the overall effect of treatment. 
An independent trial data monitoring committee consisting of two senior consultant 
paediatric neurologists, an independent medical statistician, and the trial statistician reviewed 
safety and 12-month outcome data and recommended trial continuation. 
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The trial is registered with the International Standard Randomised Controlled Trial 
Number registry, number 15239951. 
 
RESULTS 
Recruitment was between 1 September 2009 and 28 December 2012. One hundred and ten 
infants were assessed for eligibility; 63 met eligibility criteria, 40 gave consent and were 
randomized (28 males, 12 females). Participant flow is summarized in the Consolidated 
Standards of Reporting Trials flowchart (Fig. 1). 
At baseline, median gestational age at birth was 3 weeks lower in the treatment group 
than the comparison group. Mean baseline CCS-Bayley-III score was 2.8 points higher in the 
comparison group than in the treatment group. Mean baseline LCS-Bayley-III score was 2.9 
points higher in the treatment group than in the comparison group (Table II). 
Children who discontinued supplementation early and did not participate in 
subsequent study assessments were considered withdrawals. By 12 months, six treatment 
group children and one comparison group child had withdrawn (three out of six treatment 
group children and the comparison group child withdrew before supplementation started). A 
further comparison group child received minimal supplementation for 2 months before being 
lost to follow-up, leaving 14 treatment group and 18 comparison group children respectively. 
By 24 months, three further children (one treatment group and two comparison group) had 
withdrawn, leaving 13 treatment group and 16 comparison group children. 
Duration of supplementation varied between participants. Six treatment group and 10 
comparison group children completed 2 years of supplementation. A further seven treatment 
and six comparison group children completed between 1 and 2 years’ supplementation. Two 
treatment group children and one comparison group child completed more than 8 weeks but 
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less than 1 year of supplementation, and eight children completed less than 8 weeks’ 
supplementation (five in the treatment group and three in the comparison group). 
Two protocol violations occurred. One infant withdrew before supplementation but 
contributed neurodevelopmental data to the comparison group at 12 months. One infant was 
randomized to receive control supplement but received treatment supplement for 2 years. 
This child was analysed in the comparison group in the intention to treat analysis, which 
included 14 treatment group and 18 comparison group infants (Fig. 1). 
Treatment and comparison group baseline blood long-chain polyunsaturated fatty-acid 
levels were similar. Mean blood DHA and eicosapentaenoic acid levels were higher in the 
treatment group at 24 months than the comparison group (p=0.07 and p=0.02 respectively). 
Baseline CCS-Bayley-III data were available for 40 participants. Participants included 
in the intention to treat analysis had CCS-Bayley-III data at baseline and at least one other 
time point (n=32). Mean baseline CCS-Bayley-III scores were similar for the treatment and 
comparison groups. At 12 months, mean CCS-Bayley-III scores were higher for the treatment 
group than the comparison group (75.0 [SD 15.8] vs 71.1 [SD 18.8] respectively; mean 
modelled difference 4.4 [95% CI −2.6 to 11.5]) and at 24 months 77.7 (SD 19.2) versus 72.2 
(SD 19.8; mean modelled difference 4.4 [95% CI −2.8 to 11.6]); however, these differences 
were not statistically significant. There was no difference in treatment effect by visit 
(χ2[1]=0.00, p=0.99), and no overall effect of treatment (χ2[1]=1.83, p=0.18) (Fig. 2). 
Analysis of the data without minimization factors produced similar results: mean 
modelled difference was 5.88 (95% CI −1.19 to 12.95) at 12 months and 5.67 (95% CI −1.57 
to 12.92) at 24 months. There was no difference in treatment effect by visit (χ2[1]=0.00, 
p=0.95) and no overall effect of treatment (χ2[1]=3.05, p=0.08). 
Mean LCS-Bayley-III scores were non-significantly higher for treatment versus 
comparison group children both at 12 months (74.8 [SD 19.8] vs 68.2 [SD 21.0] respectively; 
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mean modelled difference 3.9 [95% CI −4.0 to 11.7] and at 24 months (78.5 [SD 25.6] versus 
69.8 [19.7]; mean modelled difference 5.5 [95% CI −2.7 to 13.6]). There was no difference in 
treatment effect by visit (no interaction) (χ2[1]=0.18, p=0.67) and no overall treatment effect 
(χ2[1]=1.61, p=0.20) (Fig. 2). 
Analysis of LCS-Bayley-III data without minimization factors produced a mean 
modelled difference of 2.9 (95% CI −7.4 to 13.2) at 12 months and 4.5 (95% CI −6.0 to 15.1) 
at 24 months. There was no difference in treatment effect by visit (χ2[1]=0.54, p=0.46), and 
no overall effect of treatment (χ2[1]=0.19, p=0.67). 
Mean motor composite scores of the Bayley-III were similar at 12 and 24 months for 
the treatment and comparison groups, both with and without inclusion of minimization 
factors in the analysis (Fig. 2). 
Mean VABS-II domain standard scores were non-significantly lower in the treatment 
than the comparison group (mean difference −5.4 [95% CI −11.8 to 1.0] and −2.7 [95% CI 
−9.1 to 3.8] at 12 and 24 months respectively; there was no evidence of an overall effect of 
treatment (χ2[1]=1.99, p=0.16) or treatment effect by visit (no interaction) (χ2[1]=0.81, 
p=0.37) (Fig. 2). Analysis of VABS-II domain standard scores without inclusion of 
minimization criteria showed little difference between groups at 12 months (mean modelled 
difference −0.4 [95% CI −8.3 to 7.5]). At 24 months, the mean modelled difference was 2.2 
(95% CI −5.7 to 10.2). There was no overall effect of treatment (χ2[1]=0.72, p=0.39) and no 
difference in treatment effect by visit (χ2[1]=0.05, p=0.82). 
There were no between-group differences in occipito-frontal circumference at 
baseline and 24 months (modelled difference in mean z-score at 24 months −0.31 [95% CI 
−0.87 to 0.26], p=0.42). Height was greater in the comparison group than the treatment 
group; the fitted differences in means were −0.57 (95% CI −1.03 to −0.11) and −0.57 (95% 
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CI −1.10 to −0.04) for 12 and 24 months respectively (p=0.02). There was no between-group 
difference in weight or triceps skinfold thickness at 12 or 24 months (data not shown). 
Overall, secondary outcome visual measures showed no differences between the 
treatment and comparison groups. Trial vision data will be reported separately (data not 
shown). 
 
DISCUSSION 
This is the first trial to explore the neurodevelopmental effect of provision of all three 
phosphatide precursors (DHA, choline, and UMP) at maximum permissible levels to infants 
with suspected CP. The trial showed a non-significant difference between infants in the 
treatment group and those in the comparison group for cognitive and language performance: 
CCS-Bayley-III scores were 4.4 points higher in the treatment group than in the comparison 
group and LCS-Bayley-III scores were 5.5 points higher in the treatment group. Despite not 
reaching statistical significance, we consider the between-group differences in Bayley-III 
cognitive and language scores of 4 to 5 points to represent clinically meaningful effects.25 
Recent nutritional intervention trials with Bayley-III as their primary outcome measure used 
point differences of 4 to 6 points to generate their sample sizes, identifying such an effect size 
to be clinically meaningful. 
Although several trials have assessed the neurodevelopmental effect of DHA 
supplementation alone, no trial has previously provided all three phosphatidylcholine 
precursors in infancy. Furthermore, infant supplementation trials so far have been in typically 
developing infants and have not considered the effects of DHA supplementation of infants 
with suspected CP.26 For all infants, supplementation began within the first 18 months of life, 
during the period of maximal brain growth and development, with the aim of supporting 
brain injury repair mechanisms after perinatal brain injury. 
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The treatment effects are not the result of a difference in macronutrient intake 
between the intervention groups (as this was optimized for both groups through dietitian 
support), or increased head circumference (brain size) among treatment group children, as 
this was similar at baseline and 24 months for both groups. There is some indication that, at 
24 months after intervention, height was greater in the comparison group children. The 
causality of this finding is unclear and requires verification in a future trial. 
Neurodevelopmental findings are similar to those of a trial conducted in neonates with risk 
factors for neurological impairment (the Dolphin neonatal trial), which demonstrated a 9-
point difference in CCS-Bayley-III and an 8.6-point difference in LCS-Bayley-III 
performance among the treatment group. Although the findings were not statistically 
significant, between-group differences were of a magnitude that could be clinically 
meaningful if replicated in an adequately powered trial (MJ Andrew et al., unpublished 
material). 
This novel trial recruited infants from UK National Health Service child development 
teams; thus children referred to the trial with suspected CP had been assessed by experienced 
multidisciplinary clinicians. Supplementation aimed to achieve DHA levels comparable to 
the maximal levels found in human breast milk (around 1% of total daily estimated fatty-acid 
intake) to optimize substrate availability to the developing brain. The high DHA dose, 
provided in combination with phosphatidylcholine precursors, choline, and UMP, through 
maximal brain growth and development was a major trial design strength. Compliance with 
supplementation was reasonable; of those who started supplement, most completed at least 1 
year of supplementation (83%). Almost half of those who started supplementation completed 
2 years’ supplementation (46%). Supplementation led to higher mean DHA levels in the 
treatment group compared with the comparison group, indicating treatment fidelity was 
reasonable. Outcome measurements were completed by one of two trained assessors. 
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There are several limitations to the interpretation of the observed treatment group 
effects on Bayley cognitive and language performance. Clinical challenges surrounding the 
early identification of infants with CP contributed to recruitment of fewer infants than 
required.27 This was exacerbated by running the Dolphin neonatal trial in the same 
geographical area, meaning some children with suspected CP had started supplementation as 
neonates and were therefore excluded from this trial. Combined with a higher than expected 
withdrawal rate, these factors resulted in the trial being underpowered. A much larger sample 
size would be necessary in any future trial that aims to replicate the findings of the current 
trial. A higher withdrawal rate in the treatment group than the comparison group may indicate 
some alteration of taste or texture of food following supplementation, despite similar 
processing of the treatment and control products. The small numbers in each group 
necessitate cautious interpretation. Stratification allowed reasonable comparison between 
groups; however, chance differences in predominant patterns of motor involvement, 
aetiology, comorbidity, age at recruitment, variation in the home environment, and 
developmental stimulation between participants during the time course of the study may have 
resulted from the small sample size. 
It is possible that the primary outcome measure used was insufficiently refined to 
identify a statistically significant treatment effect even though one existed. As childhood 
progresses, it is possible to make finer neurodevelopmental assessments using a range of 
robust assessment tools. Studies assessing the neurodevelopmental outcomes of the Dolphin 
infant cohort at preschool and school ages are currently being conducted, to establish any 
long-term effects of early nutritional supplementation that might only become identifiable as 
cognitive demands increase with age. While acknowledging the limitations of this study, if a 
treatment effect was shown in an adequately powered future study, children with CP may 
stand to benefit from nutritional supplementation in early childhood. Such findings would 
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have important implications for the nutritional management of children with CP, and advance 
our understanding of the role of nutrition in brain development after perinatal brain injury. 
Furthermore, clinically significant functional improvements in cognitive and language ability 
would have important implications for education and social participation. 
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Table I: Amounts of the active ingredients in the treatment and control supplement (in 2g 
powder) 
  
Component 
Amount per 2g powder 
Treatment Control 
Docosahexaenoic acid 37.8mg 0.4mg 
Eicosapentaenoic acid 7.8mg 0.08mg 
Arachidonic acid 4.4mg 0.02mg 
Uridine monophosphate 1.8mg 0mg 
Cytidine monophosphate 1.8mg 0mg 
Choline 10.5mg 1.38mg 
Vitamin B12 0.12μg 0.02μg 
Zinc 0.76mg 0.06mg 
Iodine 15μg 0.6μg 
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Table II: Baseline characteristics of randomized participants 
LQ, lower quartile; UQ, upper quartile; CCS-Bayley-III, Cognitive composite score – Bayley 
Scales of Infant Development (3rd edition); LCS-Bayley-III, Language composite score – 
Bayley Scales of Infant Development (3rd edition); MCS-Bayley-III, Motor composite score 
– Bayley Scales of Infant Development (3rd edition).  
 Treatment (mean number 
[SD] or median [LQ, 
UQ]) 
Comparison (mean number 
[SD] or median [LQ, UQ]) 
Numbers assigned treatment 20 20 
Sex: male/female 14/6 14/6 
Gestational age at birth (wks) 35.0 (28.0, 38.5) 38.0 (32.5, 41.0) 
Motor involvement: four 
limbs/other 
7/13 8/12 
Visual impairment: yes/no 3/17 4/16 
Corrected age at time of 
recruitment: 1–5mo/6–12mo/13–
18mo 
5/5/10 2/8/10 
Maternal educational qualification: 
qualification at 16/at 18/tertiary 
level 
9/4/5 7/8/5 
CCS-Bayley-III 72.5 (15.5) 75.3 (17.5) 
LCS-Bayley-III 77.6 (13.7) 74.7 (15.7) 
MCS-Bayley-III 65.7 (16.9) 63.4 (19.4) 
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Figure 1: Consolidated Standards of Reporting Trials flowchart. 
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Figure 2: Mean difference in treatment and comparison groups by visit for the Bayley Scales 
of Infant Development (3rd edition) composite cognitive, language, and motor score, and 
Vineland Adaptive Behavior Scales (2nd edition) domain standard score. 
 
